SCHEMBL3913632

SCHEMBL3913632

CCOC(=O)c1c(N)sc2c1CC(C)CC2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.81
MAPT P10636 11/20 0.81
HPGD P15428 9/20 0.81
KDM4E B2RXH2 7/20 0.81
GAA P10253 6/20 0.81
HSD17B10 Q99714 5/20 0.81
ALOX15 P16050 3/20 0.81
TSHR P16473 1/20 0.81
ALOX12 P18054 1/20 0.81
MAPK1 P28482 1/20 0.65
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
ADORA1 P30542 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.52
POLB P06746 2/20 0.52
RECQL P46063 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247239 0.90 ALDH1A1 (1.00) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL2949670 0.90 ALDH1A1 (1.00) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL19140590 0.88 MAPT (0.63) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL15236769 0.85 ALDH1A1 (0.62) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL8190412 0.85 ALDH1A1 (0.62) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL17321039 0.84 ALDH1A1 (0.58) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL15236795 0.84 MAPT (0.63) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL10720071 0.83 MAPT (0.56) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL15898824 0.83 MAPT (0.60) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL15236712 0.83 MAPT (0.65) ALDH1A1MAPTHPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193080-A1 ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR UNIVERSITY OF THE SCIENCES (US) 2022-06-23 US claimed
US-20090298842-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PATO JANOS 2009-12-03 US claimed
US-20090018149-A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections AXXIMA PHARMACEUTICALS AG (DE) 2009-01-15 US claimed
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor VICHEM CHEMIE KFT (HU) 2004-09-02 US claimed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220193080-A1 ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR UNIVERSITY OF THE SCIENCES (US) 2022-06-23 US disclosed
US-20220193080-A1 ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR UNIVERSITY OF THE SCIENCES (US) 2022-06-23 US disclosed
CN-113501807-A Tetrahydrobenzothiophene compound, and preparation method and application of pharmaceutical composition 重庆科技学院 2021-10-15 CN disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2020210582-A1 ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR UNIVERSITY OF THE SCIENCES (US) 2020-10-15 WO disclosed
EP-1828197-A1 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE Solvay Pharmaceuticals GmbH (DE) 2007-09-05 EP disclosed
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
WO-2006063615-A1 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE SOLVAY PHARMACEUTICALS GMBH (DE) 2006-06-22 WO disclosed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 US disclosed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 US disclosed
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor VICHEM CHEMIE KFT (HU) 2004-09-02 US disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298842-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PKLR, MASTL, BPGM ALDH1A1 4718/4885MAPT 3062/4885HPGD 964/4885
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885MAPT 1642/4885HPGD 96/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ALDH1A1 233/4885MAPT 2356/4885HPGD 218/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 ALDH1A1 229/4885MAPT 1642/4885HPGD 96/4885
US-20220193080-A1 ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR GLP1R, GPR119, GIPR ALDH1A1 4778/4885MAPT 3368/4885HPGD 4352/4885
US-20040171603-A1 Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor PKLR, PKN1, PKMYT1 ALDH1A1 4655/4885MAPT 2046/4885HPGD 852/4885
US-20090018149-A1 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections STK4, SBK3, STK17B ALDH1A1 4146/4885MAPT 2119/4885HPGD 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.